Palbace 125 mg

Palbace 125mg is a prescription medication used to treat certain types of breast cancer, including hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is a CDK4/6 inhibitor that works by blocking the activity of certain proteins that promote cancer cell growth and survival.

Composition:

• Palbociclib 125mg

Mechanism of Action:

Palbociclib works by:

1. Inhibiting the activity of cyclin-dependent kinases (CDKs) 4 and 6, which are key regulators of the cell cycle
2. Blocking the progression of the cell cycle from G1 to S phase, which can lead to apoptosis (cell death)
3. Reducing the production of proteins that promote cancer cell growth and survival

Indications:

Palbace 125mg is approved for the treatment of:

• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in combination with letrozole
• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in combination with fulvestrant

Dosage:

The recommended dosage of Palbace 125mg is:

• 125mg administered orally once daily, in combination with letrozole or fulvestrant
• The recommended duration of treatment is until disease progression or unacceptable toxicity occurs

Side Effects:

Common side effects of Palbace 125mg include:

1. Fatigue
2. Nausea and vomiting
3. Diarrhea
4. Abdominal pain
5. Headache
6. Dizziness
7. Increased risk of infections
8. Increased risk of bleeding
9. Increased risk of blood clots
10. Skin rash

Recommendation:

Palbace 125mg is recommended for patients with HR+, HER2- breast cancer who have not responded to other treatments or who have progressed on or are intolerant to other therapies.

Important Note:

• Patients taking Palbace 125mg should be closely monitored for signs of infection, bleeding, or blood clotting.
• Patients taking Palbace 125mg should avoid taking medications that may interact with it, such as warfarin or phenytoin.
• Pregnant or breastfeeding women should not use Palbace 125mg, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Palbace 125mg and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of bleeding disorders should be closely monitored while taking Palbace 125mg.
• Patients with a history of liver disease or liver dysfunction should be closely monitored while taking Palbace 125mg.

Contraindications:

• Patients who are allergic to palbociclib or any other component of Palbace 125mg should not use it.
• Patients who are pregnant or breastfeeding should not use Palbace 125mg.
• Patients with severe liver disease or liver failure should not use Palbace 125mg.

Warnings:

• Palbace 125mg can cause severe neutropenia (low white blood cell count), which can increase the risk of infection.
• Patients with a history of bleeding disorders should be closely monitored while taking Palbace 125mg.
• Patients should report any changes in their blood cell count or symptoms of infection to their healthcare provider immediately.